Clinical Significance of Factor XIII Activity and Monocyte-Derived Microparticles in Cancer Patients

References

• Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016;133(11):1104–1114. doi:10.1161/CIRCULATIONAHA.115.020406
   PubMed Web of Science ®Google Scholar
• Bonnie KY. Cardio-oncology. In: Braunwald E, editor. Heart Disease. 11thed. Philadelphia: Saunders; 2018:1641–1650.
   Google Scholar
• Chang HM, Okwuosa TM, Scarabelli T, Moudgil R, Yeh ETH. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management-part 2. J Am Coll Cardiol. 2017;70(20):2552–2565. doi:10.1016/j.jacc.2017.09.1095
   PubMedGoogle Scholar
• Okwuosa TM, Prabhu N, Patel H, et al. The cardiologist and the cancer patient: challenges to cardio-oncology (or onco-cardiology) and call to action. J Am Coll Cardiol. 2018;72(2):228–232. doi:10.1016/j.jacc.2018.04.043
   PubMed Web of Science ®Google Scholar
• Edwards BK, Noone AM, Mariotto AB, et al. Annual report to the nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120(9):1290–1314. doi:10.1002/cncr.28509
   PubMed Web of Science ®Google Scholar
• Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007;25(34):5490–5505. doi:10.1200/JCO.2007.14.1283
   PubMed Web of Science ®Google Scholar
• Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632–634. doi:10.1111/j.1538-7836.2007.02374.x
   PubMed Web of Science ®Google Scholar
• Khorana AA. Venous thromboembolism and prognosis in cancer. Thromb Res. 2010;125(6):490–493. doi:10.1016/j.thromres.2009.12.023
   PubMed Web of Science ®Google Scholar
• Mukai M, Komori K, Oka T. Mechanism and management of cancer chemotherapy-induced atherosclerosis. J Atheroscler Thromb. 2018;25(10):994–1002. doi:10.5551/jat.RV17027
   PubMed Web of Science ®Google Scholar
• Muszbek L, Bereczky Z, Bagoly Z, et al. Factor XIII: a coagulation factor with multiple plasmatic and cellular functions. Physiol Rev. 2011;91(3):931–972.
   PubMed Web of Science ®Google Scholar
• Ichinose A. Factor XIII is a key molecule at the intersection of coagulation and fibrinolysis as well as inflammation and infection control. Int J Hematol. 2012;95(4):362–370. doi:10.1007/s12185-012-1064-3
   PubMed Web of Science ®Google Scholar
• Smith KA, Pease RJ, Avery CA, et al. The activation peptide cleft exposed by thrombin cleavage of FXIII-A2 contains a recognition site for the fibrinogen α chain. Blood. 2013;121(11):2117–2126. doi:10.1182/blood-2012-07-446393
   PubMed Web of Science ®Google Scholar
• Fraser SR, Booth NA, Mutch NJ. The antifibrinolytic function of factor XIII is exclusively expressed through 2-antiplasmin cross-linking. Blood. 2011;117(23):6371–6374.
   PubMed Web of Science ®Google Scholar
• Mitchell JL, Lionikiene AS, Fraser SR, et al. Functional factor XIII-A is exposed on the stimulated platelet surface. Blood. 2014;124(26):3982–3990. doi:10.1182/blood-2014-06-583070
   PubMed Web of Science ®Google Scholar
• Schroeder V, Kohler HP. New developments in the area of factor XIII. J Thromb Haemost. 2013;11(2):234–244. doi:10.1111/jth.12074
   PubMed Web of Science ®Google Scholar
• Tahlan A, Ahluwalia J. Factor XIII: congenital deficiency factor XIII, acquired deficiency, factor XIII A-subunit, and factor XIII B-subunit. Arch Pathol Lab Med. 2014;138(2):278–281. doi:10.5858/arpa.2012-0639-RS
   PubMed Web of Science ®Google Scholar
• Shi DY, Wang SJ. Advances of coagulation factor XIII. Chin Med J. 2017;130(2):219–223. doi:10.4103/0366-6999.198007
   PubMed Web of Science ®Google Scholar
• Kreutz RP, Schmeisser G, Schaffter A, et al. Prediction of ischemic events after percutaneous coronary intervention: thrombelastography profiles and factor XIIIa activity. TH Open. 2018;2(2):e173–181. doi:10.1055/s-0038-1645876
   PubMedGoogle Scholar
• Gonçalves E. Lopes da Silva R, Varandas J, Diniz MJ. Acute promyelocytic leukaemia associated factor XIII deficiency presenting as retro-bulbar haematoma. Thromb Res. 2012;129(6):810–811. doi:10.1016/j.thromres.2012.03.008
   PubMed Web of Science ®Google Scholar
• Lee SH, Suh IB, Lee EJ, et al. Relationships of coagulation factor XIII activity with cell-type and stage of non-small cell lung cancer. Yonsei Med J. 2013;54(6):1394–1399. doi:10.3349/ymj.2013.54.6.1394
   PubMed Web of Science ®Google Scholar
• Omoto S, Nomura S, Shouzu A, et al. Detection of monocyte-derived microparticles in patients with type II diabetes mellitus. Diabetologia. 2002;45(4):550–555. doi:10.1007/s00125-001-0772-7
   PubMed Web of Science ®Google Scholar
• Matsumoto N, Nomura S, Kamihata H, et al. Increased level of oxidized LDL-dependent monocyte-derived microparticles in acute coronary syndrome. Thromb Haemost. 2004;91(1):146–154. doi:10.1160/TH03-04-0247
   PubMed Web of Science ®Google Scholar
• Nomura S, Shouzu A, Omoto S, et al. Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus. Thromb Res. 2006;117(4):385–392. doi:10.1016/j.thromres.2005.04.008
   PubMed Web of Science ®Google Scholar
• Colotta F, Borre A, Wang JM, et al. Expression of monocyte chemotactic cytokine by human mononuclear phagocytes. J Immunol. 1992;148(3):760–765.
   PubMed Web of Science ®Google Scholar
• Fries JWU, Williams AJ, Atkins RC, et al. Expression of VCAM-1 and E-selectin an in vivo model of endothelial activation. Am J Pathol. 1993;143(3):725–737.
   PubMed Web of Science ®Google Scholar
• Jsffe ES. Introduction and over view of the classification of lymphoid neoplasmas. In: Swerdlow SH, editor. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2017:pp190–198.
   Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–3068. doi:10.1200/JCO.2013.54.8800
   PubMed Web of Science ®Google Scholar
• Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–3420. doi:10.1200/JCO.2005.04.242
   PubMed Web of Science ®Google Scholar
• Rami-Porta R, Bolejack V, Giroux DJ, et al. The IASLC lung cancer staging project: the new database to inform the eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 2014;9(11):1618–1624. doi:10.1097/JTO.0000000000000334
   PubMed Web of Science ®Google Scholar
• Fickenscher K, Aab A, Stuber W. A photometric assay for blood coagulation factor XIII. Thromb Haemost. 1991;65(5):535–540. doi:10.1055/s-0038-1648185
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–548. doi:10.1016/S1470-2045(14)70442-5
   PubMed Web of Science ®Google Scholar
• Varki A. Trousseau’s syndrome: multiple definition and multiple mechanisms. Blood. 2007;110(6):1723–1729. doi:10.1182/blood-2006-10-053736
   PubMed Web of Science ®Google Scholar
• Ikushima S, Ono R, Fukuda K, et al. Trousseau’s syndrome: cancer-associated thrombosis. Jpn J Clin Oncol. 2016;46(3):204–208. doi:10.1093/jjco/hyv165
   PubMed Web of Science ®Google Scholar
• Zöller B, Melander O, Svensson P, Engström G. Red cell distribution width and risk for venous thromboembolism: a population-based cohort study. Thromb Res. 2014;133(3):334–339. doi:10.1016/j.thromres.2013.12.013
   PubMed Web of Science ®Google Scholar
• Riedl J, Kaider A, Reitter EM, et al. Association of mean platelet volume with risk of venous thromboembolism and mortality in patients with cancer. Results from the Vienna Cancer and Thrombosis Study (CATS). Thromb Haemost. 2014;111(4):670–678. doi:10.1160/TH13-07-0603
   PubMed Web of Science ®Google Scholar
• Díaz JM, Boietti BR, Vazquez FJ, et al. Mean platelet volume as a prognostic factor for venous thromboembolic disease. Rev Med Chil. 2019;147(2):145–152. doi:10.4067/s0034-98872019000200145
   PubMed Web of Science ®Google Scholar
• Inagaki N, Kibata K, Tamaki T, Shimizu T, Nomura S. Prognostic impact of the mean platelet volume/platelet count ratio in terms of survival in advanced non-small cell lung cancer. Lung Cancer. 2015;83(1):97–101. doi:10.1016/j.lungcan.2013.08.020
   Web of Science ®Google Scholar
• Cui CJ, Wang GJ, Yang S, Huang SK, Qiao R, Cui W. Tissue factor-bearing MPs and the risk of venous thrombosis in cancer patients: a meta-analysis. Sci Rep. 2018;8(1):1675. doi:10.1038/s41598-018-19889-8
   PubMedGoogle Scholar
• Tesselaar ME, Romijin FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto S. Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost. 2007;5(3):520–527. doi:10.1111/j.1538-7836.2007.02369.x
   PubMed Web of Science ®Google Scholar
• Zwicker JI, Liebman HA, Neuberg D, et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res. 2009;15(22):6830–6840. doi:10.1158/1078-0432.CCR-09-0371
   PubMed Web of Science ®Google Scholar
• Manly DA, Wang J, Glover SL, et al. Increased microparticle tissue factor activity in cancer patients with venous thromboembolism. Thromb Res. 2010;125(6):511–512. doi:10.1016/j.thromres.2009.09.019
   PubMed Web of Science ®Google Scholar
• Campello E, Spiezial L, Radu CM, et al. Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism. Thromb Res. 2011;127(5):473–477. doi:10.1016/j.thromres.2011.01.002
   PubMed Web of Science ®Google Scholar
• Geddings JE, Mackman N. Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. Blood. 2013;122(11):1873–1880. doi:10.1182/blood-2013-04-460139
   PubMed Web of Science ®Google Scholar
• Falati S, Liu Q, Gross P, et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med. 2003;197(11):1585–1598. doi:10.1084/jem.20021868
   PubMed Web of Science ®Google Scholar
• Del Conde I, Shrimpton CN, Thiagarajan P, López JA. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood. 2005;106(5):1604–1611. doi:10.1182/blood-2004-03-1095
   PubMed Web of Science ®Google Scholar
• Pang W, Su J, Wand Y, et al. Pancreatic cancer-secreted miR-155 implicates in the conversion from normal fibroblasts to cancer-associated fibroblasts. Cancer Sci. 2015;106(10):1362–1369. doi:10.1111/cas.12747
   PubMed Web of Science ®Google Scholar
• Geddings JE, Hisada Y, Boulaftali Y, et al. Tissue factor-positive tumor microvesicles activate platelets and enhance thrombosis in mice. J Thromb Haemost. 2016;14(1):153–166. doi:10.1111/jth.13181
   PubMed Web of Science ®Google Scholar
• Zarà M, Guidetti GF, Camera M, et al. Biology and role of extracellular vesicle (EVs) in the pathogenesis of thrombosis. Int J Mol Sci. 2019;20(11):E2840. doi:10.3390/ijms20112840
   PubMed Web of Science ®Google Scholar
• Bereczky Z, Balogh E, Katona E, Czuriga I, Edes I, Muszbek L. Elevated factor XIII level and the risk of myocardial infarction in women. Haematologica. 2007;92(2):287–288. doi:10.3324/haematol.10647
   PubMed Web of Science ®Google Scholar
• Ambroziak M, Kurylowicz A, Budaj A. Increased coagulation factor XIII activity but not genetic variants of coagulation factors is associated with myocardial infarction in young patients. J Thromb Thrombolys. 2019;48(3):519–527. doi:10.1007/s11239-019-01856-3
   PubMed Web of Science ®Google Scholar
• Owens AP 3rd, Mackman N. Microparticles in hemostasis and thrombosis. Cir Res. 2011;108(10):1284–1297. doi:10.1161/CIRCRESAHA.110.233056
   PubMed Web of Science ®Google Scholar
• Weiss R, Gröger M, Rauscher S, et al. Differential interaction of platelet-derived extracellular vesicles with leukocyte subsets in human whole blood. Sci Rep. 2018;8(1):6598. doi:10.1038/s41598-018-25047-x
   PubMedGoogle Scholar